FDA awards nine companies priority review vouchers for expedited drug approvals
TL;DR Summary
The FDA has awarded nine companies, including Regeneron and Revolution Medicines, a new 'national priority' voucher to expedite drug reviews, potentially reducing evaluation time to one or two months for treatments addressing urgent health needs, with the program currently limited to select drugs meeting specific criteria.
- FDA awards 9 companies a new ‘national priority’ voucher to speed drug reviews BioPharma Dive
- FDA unveils drugs to receive expedited review in support of ‘national priorities’ AP News
- US FDA announces recipients of national priority vouchers Reuters
- FDA unveils nine drugs getting streamlined reviews Axios
- FDA names 9 first recipients of 1- to 2-month priority review vouchers Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
93%
623 → 46 words
Want the full story? Read the original article
Read on BioPharma Dive